Orchid Pharma Limited - Asset Resilience Ratio
Orchid Pharma Limited (ORCHPHARMA) has an Asset Resilience Ratio of 6.25% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Also explore ORCHPHARMA total assets for the complete picture of this company's asset base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2025)
This chart shows how Orchid Pharma Limited's Asset Resilience Ratio has changed over time. See ORCHPHARMA equity to assets ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Orchid Pharma Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Orchid Pharma Limited.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs1.08 Billion | 6.25% |
| Total Liquid Assets | Rs1.08 Billion | 6.25% |
Asset Resilience Insights
- Limited Liquidity: Orchid Pharma Limited maintains only 6.25% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Orchid Pharma Limited Industry Peers by Asset Resilience Ratio
Compare Orchid Pharma Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Ajanta Pharma Limited
NSE:AJANTPHARM |
Drug Manufacturers - Specialty & Generic | 14.99% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Guizhou Bailing Group Pharmaceutical Co Ltd
SHE:002424 |
Drug Manufacturers - Specialty & Generic | 2.09% |
|
Dezhan HealthCare Co Ltd
SHE:000813 |
Drug Manufacturers - Specialty & Generic | 0.15% |
Annual Asset Resilience Ratio for Orchid Pharma Limited (2004–2025)
The table below shows the annual Asset Resilience Ratio data for Orchid Pharma Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 9.21% | Rs1.55 Billion ≈ $16.81 Million |
Rs16.88 Billion ≈ $182.54 Million |
+9.15pp |
| 2024-03-31 | 0.06% | Rs9.23 Million ≈ $99.81K |
Rs15.54 Billion ≈ $168.05 Million |
-0.27pp |
| 2023-03-31 | 0.33% | Rs40.15 Million ≈ $434.16K |
Rs12.25 Billion ≈ $132.50 Million |
+0.33pp |
| 2022-03-31 | 0.00% | Rs59.00K ≈ $638.06 |
Rs11.11 Billion ≈ $120.10 Million |
-1.28pp |
| 2021-03-31 | 1.28% | Rs158.21 Million ≈ $1.71 Million |
Rs12.37 Billion ≈ $133.80 Million |
+1.28pp |
| 2020-03-31 | 0.00% | Rs122.00K ≈ $1.32K |
Rs14.60 Billion ≈ $157.88 Million |
-7.58pp |
| 2019-03-31 | 7.58% | Rs2.33 Billion ≈ $25.22 Million |
Rs30.77 Billion ≈ $332.77 Million |
-1.07pp |
| 2018-03-31 | 8.65% | Rs2.70 Billion ≈ $29.25 Million |
Rs31.25 Billion ≈ $338.00 Million |
+1.39pp |
| 2017-03-31 | 7.26% | Rs2.36 Billion ≈ $25.57 Million |
Rs32.56 Billion ≈ $352.08 Million |
+7.28pp |
| 2016-03-31 | -0.02% | Rs-6.73 Million ≈ $-72.80K |
Rs38.62 Billion ≈ $417.67 Million |
-0.44pp |
| 2011-03-31 | 0.42% | Rs171.78 Million ≈ $1.86 Million |
Rs40.71 Billion ≈ $440.21 Million |
-5.03pp |
| 2010-03-31 | 5.45% | Rs2.06 Billion ≈ $22.25 Million |
Rs37.74 Billion ≈ $408.10 Million |
+3.04pp |
| 2009-03-31 | 2.41% | Rs1.02 Billion ≈ $11.04 Million |
Rs42.34 Billion ≈ $457.89 Million |
-0.61pp |
| 2008-03-31 | 3.02% | Rs1.05 Billion ≈ $11.36 Million |
Rs34.84 Billion ≈ $376.81 Million |
-1.09pp |
| 2007-03-31 | 4.10% | Rs1.19 Billion ≈ $12.83 Million |
Rs28.91 Billion ≈ $312.65 Million |
-0.26pp |
| 2006-03-31 | 4.36% | Rs945.99 Million ≈ $10.23 Million |
Rs21.69 Billion ≈ $234.52 Million |
+0.73pp |
| 2005-03-31 | 3.64% | Rs659.20 Million ≈ $7.13 Million |
Rs18.12 Billion ≈ $196.01 Million |
+2.74pp |
| 2004-03-31 | 0.90% | Rs128.15 Million ≈ $1.39 Million |
Rs14.28 Billion ≈ $154.41 Million |
-- |
About Orchid Pharma Limited
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins; human and veterinary products; and antibiotics, including betalactam, m… Read more